Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PIMREG pseudogene 1 (PIMREGP1) is classified as a pseudogene derived from the parental PIMREG (PICALM interacting mitotic regulator) gene. Pseudogenes are genetically similar to protein-coding genes but typically lack the capacity to encode functional proteins due to mutations, truncations, or other disabling changes[3][6]. While some pseudogenes are transcribed as non-coding RNAs and may regulate their parental gene, there is currently no evidence that PIMREG pseudogene 1 has such functions. It is therefore *not* considered a therapeutic target, does not act as a biomarker or a molecular actor in disease, and has no associated mechanism of action, interacting drugs, or known safety concerns. All established molecular and disease associations in the literature refer to the protein-coding PIMREG gene, not its pseudogene derivatives[1][2][4][5].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PIMREG pseudogene 1 (PIMREGP1).